Treatment of AML cells with idelalisib inhibited ribosomal RNA (rRNA) synthesis and cell proliferation by suppressing Akt phosphorylation with a greater effect observed in cells expressing higher levels of p110δ [124]. Here, AKT1 is linked to acute myeloid leukemia.